Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Radiation Oncology
Erschienen in: Journal of Radiation Oncology 3/2012

01.09.2012 | Review

Conventional radiation therapy for brain metastases

verfasst von: Caroline Chung, May Tsao, Stephen Lutz

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Conventional radiotherapy in the form of whole brain radiation treatment has been a longstanding treatment for brain metastases, and it continues to provide effective palliation as monotherapy and in combination with local and systemic treatments. Advances in systemic therapy have improved survival with metastatic disease, and in those patients with better prognostic factors, more aggressive local therapeutic approaches for brain metastases appear to benefit their survival and intracranial tumor control. Increased treatment intensity and longer survival following treatment of brain metastases have raised concerns about persistent treatment-related neurocognitive toxicities and the resulting impact on quality of life. Technological advances in conventional radiotherapy planning and delivery have led to novel approaches that may increase intracranial tumor control while minimizing the treatment-related toxicities of therapy. These innovative approaches include intensity-modulated radiotherapy, new image-guidance techniques, and volumetric modulated arc therapy, which allow for the delivery of whole brain radiotherapy with integrated boost treatment to the visible disease while sparing the hippocampal regions or delivery of hypofractionated radiotherapy to larger metastatic targets that may not be amenable to radiosurgery boost or salvage treatment.
Literatur
1.
Sneed PK et al (1999) Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43(3):549–558PubMedCrossRef
2.
Gaspar LE et al (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):17–32PubMedCrossRef
3.
Tsao MN et al (2006) Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 3:CD003869PubMed
4.
Rades D et al (2010) Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 77(2):537–541PubMedCrossRef
5.
Rades D, Heisterkamp C, Schild SE (2010) Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys 78(2):398–403PubMedCrossRef
6.
Graham PH, Bucci J, Browne L (2010) Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int J Radiat Oncol Biol Phys 77(3):648–654PubMedCrossRef
7.
Rades D et al (2011) Shorter-course whole-brain radiotherapy for brain metastases in elderly patients. Int J Radiat Oncol Biol Phys 81(4):e469–e473PubMedCrossRef
8.
Bohlen G et al (2010) Short-course whole-brain radiotherapy (WBRT) for brain metastases due to small-cell lung cancer (SCLC). Clin Neurol Neurosurg 112(3):183–187PubMedCrossRef
9.
Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751PubMedCrossRef
10.
Gaspar LE et al (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47(4):1001–1006PubMedCrossRef
11.
Sperduto CM et al (2008) A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109(Suppl):87–89PubMed
12.
Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514PubMedCrossRef
13.
Sperduto PW et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661PubMedCrossRef
14.
Wong J et al (2009) Symptoms and quality of life in cancer patients with brain metastases following palliative radiotherapy. Int J Radiat Oncol Biol Phys 75(4):1125–1131PubMedCrossRef
15.
Komosinska K et al (2010) Prospective evaluation of the palliative effect of whole-brain radiotherapy in patients with brain metastases and poor performance status. Acta Oncol 49(3):382–388PubMedCrossRef
16.
Auperin A et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341(7):476–484PubMedCrossRef
17.
Paumier A, Cuenca X, Le Pechoux C (2011) Prophylactic cranial irradiation in lung cancer. Cancer Treat Rev 37(4):261–265PubMedCrossRef
18.
Lester JF, MacBeth FR, Coles B (2005) Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. Int J Radiat Oncol Biol Phys 63(3):690–694PubMedCrossRef
19.
Giuliani M et al (2010) Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer 116(24):5694–5699PubMedCrossRef
20.
Slotman BJ et al (2009) Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 27(1):78–84PubMedCrossRef
21.
Sun A et al (2011) Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 29(3):279–286PubMedCrossRef
22.
Sas-Korczynska B, Korzeniowski S, Wojcik E (2010) Comparison of the effectiveness of "late" and "early" prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Strahlenther Onkol 186(6):315–319PubMedCrossRef
23.
Le Pechoux C et al (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 22(5):1154–1163PubMedCrossRef
24.
Sadikov E et al (2007) Value of whole brain re-irradiation for brain metastases–single centre experience. Clin Oncol (R Coll Radiol) 19(7):532–538CrossRef
25.
Wong WW et al (1996) Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 34(3):585–590PubMedCrossRef
26.
Patil CG et al (2010) Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev (6): p CD006121
27.
Tsao, M., W. Xu, and A. Sahgal (2011) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer
28.
Hart MG, et al (2005) Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev (1): p CD003292
29.
Mintz AH et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78(7):1470–1476PubMedCrossRef
30.
Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141PubMedCrossRef
31.
Li J et al (2008) Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71(1):64–70PubMedCrossRef
32.
Welzel G et al (2008) Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 72(5):1311–1318PubMedCrossRef
33.
Aoyama H et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68(5):1388–1395PubMedCrossRef
34.
Chang EL et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044PubMedCrossRef
35.
Szerlip N et al (2011) Factors impacting volumetric white matter changes following whole brain radiation therapy. J Neurooncol 103(1):111–119PubMedCrossRef
36.
Conill C et al (2007) Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol 9(9):590–595PubMedCrossRef
37.
Lee EH et al (1992) Protein synthesis in the hippocampus associated with memory facilitation by corticotropin-releasing factor in rats. Peptides 13(5):927–937PubMedCrossRef
38.
Mizumatsu S et al (2003) Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 63(14):4021–4027PubMed
39.
Raber J et al (2004) Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 162(1):39–47PubMedCrossRef
40.
Meyers CA et al (2000) Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 46(1):51–55PubMedCrossRef
41.
Nagai R et al (2000) Selective vulnerability to radiation in the hippocampal dentate granule cells. Surg Neurol 53(5):503–506, discussion 506-7PubMedCrossRef
42.
Gutierrez AN et al (2007) Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 69(2):589–597PubMedCrossRef
43.
Hsu F et al (2010) Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 76(5):1480–1485PubMedCrossRef
44.
Gondi V et al (2010) Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 78(4):1244–1252PubMedCrossRef
45.
Tarnawski R et al (2011) Feasibility of reducing the irradiation dose in regions of active neurogenesis for prophylactic cranial irradiation in patients with small-cell lung cancer. Neoplasma 58(6):507–515PubMedCrossRef
46.
Rodrigues G et al (2011) Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. Int J Radiat Oncol Biol Phys 80(4):1128–1133PubMedCrossRef
47.
Bender ET, Tome WA (2011) Distribution of brain metastases: implications for non-uniform dose prescriptions. Br J Radiol 84(1003):649–658PubMedCrossRef
48.
Aoyama H et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491PubMedCrossRef
49.
Pirzkall A et al (1998) Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16(11):3563–3569PubMed
50.
Rades D et al (2008) Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT + SRS) for one to three brain metastases. Strahlenther Onkol 184(12):655–662PubMedCrossRef
51.
Aoyama H et al (2003) Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys 56(3):793–800PubMedCrossRef
52.
Ernst-Stecken A et al (2006) Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol 81(1):18–24PubMedCrossRef
53.
Quantin X, Bozonnat MC, Pujol JL (2010) Recursive Partitioning Analysis Groups II-III brain metastases of non-small cell lung cancer: a phase II randomized study comparing two concurrent chemoradiotherapy regimens. J Thorac Oncol 5(6):846–851PubMedCrossRef
54.
Lind JS et al (2009) Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 74(5):1391–1396PubMedCrossRef
55.
Chargari C et al (2009) Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neurooncol 93(3):379–384PubMedCrossRef
56.
Hedde JP et al (2007) A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. Int J Radiat Oncol Biol Phys 68(3):839–844PubMedCrossRef
57.
Neuhaus T et al (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 100(2):291–297PubMedCrossRef
58.
Cassier PA et al (2008) A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer 113(9):2532–2538PubMedCrossRef
59.
Viani GA et al (2009) Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res 28:1PubMedCrossRef
60.
Reid JM et al (1997) Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3(12 Pt 1):2393–2398PubMed
61.
Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef
62.
Antonadou D et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20(17):3644–3650PubMedCrossRef
63.
Verger E et al (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61(1):185–191PubMedCrossRef
64.
Siena S et al (2010) Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 21(3):655–661PubMedCrossRef
65.
Hofmann M et al (2006) Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76(1):59–64PubMedCrossRef
66.
Khuntia D, Mehta M (2004) Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4(6):981–989PubMedCrossRef
67.
Mehta MP et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13):2529–2536PubMedCrossRef
68.
Mehta MP et al (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73(4):1069–1076PubMedCrossRef
69.
Chargari C et al (2011) Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys 81(3):631–636PubMedCrossRef
70.
Burris HA 3rd et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23):5305–5313PubMedCrossRef
71.
Pesce GA et al (2012) Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 48(3):377–384PubMedCrossRef
72.
Borgelt B et al (1981) Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7(12):1633–1638PubMedCrossRef
73.
Kurtz JM et al (1981) The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7(7):891–895PubMedCrossRef
74.
Chatani M et al (1985) Whole brain irradiation for metastases from lung carcinoma. A clinical investigation Acta Radiol Oncol 24(4):311–314
75.
Komarnicky LT et al (1991) A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20(1):53–58PubMedCrossRef
76.
Haie-Meder C et al (1993) Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26(2):111–116PubMedCrossRef
77.
Chatani M et al (1994) Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170(3):155–161PubMed
78.
Priestman TJ et al (1996) Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 8(5):308–315CrossRef
79.
Murray KJ et al (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39(3):571–574PubMedCrossRef
80.
Davey P et al (2008) A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol 88(2):173–176PubMedCrossRef
81.
Son CH et al (2012) Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 82(2):e167–e172PubMedCrossRef
82.
Cooper JS, Steinfeld AD, Lerch IA (1990) Cerebral metastases: value of reirradiation in selected patients. Radiology 174(3 Pt 1):883–885PubMed
83.
Vecht CJ et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590PubMedCrossRef
84.
Patchell RA et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500PubMedCrossRef
Metadaten
Titel
Conventional radiation therapy for brain metastases
verfasst von
Caroline Chung
May Tsao
Stephen Lutz
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2012
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-012-0046-7

Weitere Artikel der Ausgabe 3/2012

Journal of Radiation Oncology 3/2012 Zur Ausgabe

Review

A review of palliative radiotherapy for lung cancer and lung metastases

Original Research

Radiosensitization of cervical cancer xenografts by arsenic trioxide and the role of VEGF and Ku70

Review

Radiation therapy for primary and metastatic tumors of the liver

Original Research

Pattern of failure after high-dose thoracic radiation for non-small cell lung cancer: the University of Michigan experience

Editorial

Palliative radiotherapy: the union of advanced technology with prudent end-of-life care

Review

Stereotactic radiosurgery for brain metastases: current status and future directions

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise